Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis
Ayako Suzuki,
Fumihiro Yamaguchi,
Masayuki Maeda,
Miyuki Hashiguchi,
Nobuyuki Kabasawa,
Jun Sasaki,
Tokutada Sato,
Masaki Fuyama,
Yohei Yamazaki,
Kei Endo,
Kae Iwata,
Sei Kobayashi,
Hisato Fujihara
Affiliations
Ayako Suzuki
Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Fumihiro Yamaguchi
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Masayuki Maeda
Division of Infection Control Sciences, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo 142-8555, Japan
Miyuki Hashiguchi
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Nobuyuki Kabasawa
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Jun Sasaki
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Tokutada Sato
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Masaki Fuyama
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Yohei Yamazaki
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Kei Endo
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Kae Iwata
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Sei Kobayashi
Antimicrobial Stewardship Team, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
Hisato Fujihara
Department of Pharmacy, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan
As antibiotic resistance has become a global problem, the intervention of an antimicrobial stewardship team (AST) is warranted. In hematological disorders, infectious complications are crucial owing to abnormal neutrophil function and decreased cell-mediated immunity. Despite the widespread implementation of AST intervention, the effectiveness of stewardship practices for immunocompromised patients remains uncertain. We determined the effect of AST interventions on carbapenem therapy in the department of hematology. Patients admitted to the department and undergoing carbapenem therapy were enrolled. We compared carbapenem use between the pre-AST (April 2016–March 2018) and post-AST (April 2018–March 2021) periods. Factors associated with long-term carbapenem therapy were investigated. Overall, 515 episodes of carbapenem therapy in 264 patients in the department were evaluated. According to the interrupted time series analysis, the number of days of therapy decreased with AST intervention (β = −0.263, p = 0.011). In multivariate analysis, predictive factors associated with long-term carbapenem therapy (>8 days) were outpatient onset, chronic obstructive pulmonary disease, acute myeloid leukemia, multiple myeloma, and infection with resistant bacteria (such as extended spectrum β-lactamases and AmpC) (95% confidence interval, 1.030–2.818, 1.067–66.667, 1.057–2.782, 0.168–0.742, and 1.382–5.750, respectively). The AST intervention reduced carbapenem use in patients with hematological disorders.